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Clinical review
Recent advances
International perspectives on health inequalities and
policy
David A Leon, Gill Walt, Lucy Gilson
Inequalities and inequities in health have long been cen›
tral to the concerns of public health. Governments in
several countries, including the United Kingdom, have
recently shown renewed interest in tackling these issues.1
Concerted attempts have also been made to push them
up the global health policy agenda,2–4 and at the same
time international agencies and donors are giving prior›
ity to efforts to reduce poverty. In this article we provide
an overview of the current debates around inequity,
inequalities, poverty, and health, drawing together
current international understandings of the problem.
Poverty and health: powerful connection
Although targeting “the poor” is clearly important,
inequalities and inequities in health are not only about
the plight of the most deprived in each society. In many
low income countries, over half the population may be
living in poverty and those who are not will still be living
in circumstances that contribute to the poor health of
the country as a whole. Even in high income countries,
where there is little absolute poverty, there are fine and
graduated inequalities in health status that span the full
socioeconomic spectrum. For example, in a study of
300 000 men in the United States, mortality declined
progressively across 12 categories of household income
from less than $7500 (£5000) to more than $32 499.5
Although not all governments perceive inequalities
in wealth and health to be something the public sector
can or should address, all governments are interested
in improving economic growth. Under the leadership
of Gro Harlem Bruntland, the World Health Organiza›
tion now argues forcibly that health is key to reducing
poverty and to development. If improving health can
have a positive effect on economic growth, then health
should become a central priority of every government:
“Because ill›health traps people in poverty, sustained
investment in the health of the poor could provide a
policy lever for alleviating persistent poverty.”6
This emphasis on the potential causal link running
from ill health to poverty, rather than vice versa, is con›
tentious.7 The evidence base to support the wealth cre›
ating potential of improved health is far less substantial
than the evidence relating poor health to poverty.
Nevertheless, the causal links between poverty and
health clearly must run in both directions to some
degree and can generate a vicious or virtuous cycle.
This complexity needs to be accounted for in concep›
tual models linking health with wealth or poverty and
needs to inform strategies aimed at improving health
and reducing poverty and inequalities in wealth. How›
ever, it is important not to lose sight of the intrinsic
value of alleviating poverty and ill health. Poverty and
ill health impair the capability of individuals to realise
their own goals—and redressing that damage cannot
be reduced to the economics of wealth creation.8
This leads to the question of the best economic
strategy for improving health and welfare. Positions are
divided. One argument is that priority should be given
to promoting economic growth so as to accumulate
sufficient wealth to then (and only then) invest
adequately in programmes to tackle ill health and pov›
erty. A second argument advocates a “support led”
strategy. Even in countries where economic growth is
minimal, intelligent and equitable investment in social
policies can improve health and welfare.9 This view is
consistent with the strikingly high life expectancy in
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countries such as China, Sri Lanka, and Costa Rica,
where per capita wealth and expenditure on health are
low by international standards (fig).
The figure provides a powerful summary of global
inequalities in life expectancy and inequities in health
expenditure. It also suggests that, between countries, per
capita health expenditure bears little relation to life
expectancy. The world is divided in two. Just over half the
countries shown have an annual per capita expenditure
of less than $500, one seventh of that of the United
States. In this group of low spending countries there is
huge variation in life expectancy. Conversely, in medium
and high expenditure countries, there is huge variation
in per capita expenditure, which shows almost no
relation to life expectancy. Much of the international
variation in mortality has to be accounted for by factors
determining differences in occurrence of disease. This
will include the effects of investment in the social sector,
particularly in education, as well as in public health over
the long term.
Contrasting perceptions
Health inequalities and inequities within countries are
not understood in the same way throughout the world
(box). In countries such as the United Kingdom,
Sweden, and the Netherlands, much of the research on
inequalities in health has focused on the mechanisms
that generate socioeconomic gradients in ill health and
mortality. From this perspective, inequalities in health
are mainly a function of the aetiology of disease, and
the policy solutions that arise are around primary pre›
vention. In low and middle income countries, by
contrast, people working on inequalities in health tend
to see the problem as one of devising policies to ensure
more equitable provision of health care.
There are exceptions to this. For example, in the
United States, concern about equity of access to
adequate health care runs alongside an active research
base on the determinants of inequalities in incidence of
disease. Nevertheless, in many high income countries, as
in western Europe, access to health services is relatively
universal and not strongly dependent on socioeconomic
circumstances or geography. In developing countries,
however, the issue of organising and funding the health
sector has been more central to inequalities in health.
This has partly been a response to the pressure from
international financial institutions to reduce govern›
ment expenditure on health and to reorganise the
health sector. Many people have seen the pressure as a
major threat to equity.11
Focusing on equity of provision of health care in the
developing world therefore has a compelling logic.
Nevertheless, the forces producing inequalities in health
status in developing countries need to be given more
attention than they are at present. By the same token, the
issue of access to health services must receive more
attention in developed countries. Much healthcare
reform the world over has been driven by a set of tech›
nocratic principles that emphasise efficiency and
effectiveness and give little consideration to equity.12
Measuring inequalities in health status
From an international perspective, there are problems
in making valid comparisons of inequalities in health
between socioeconomic groups defined in various ways,
including occupational social class or educational level.13
Despite these difficulties, research has established real
international variations in the magnitude of socioeco›
nomic differences in health status and mortality for spe›
cific diseases. This shows that socioeconomic variation is
not a fixed and inevitable feature of society.14
Despite the achievements of the large body of
research based on analysis of social groups, it has
recently been proposed that this approach should be
abandoned.15 Gakidou et al advocate that, rather than
looking at the way in which health or disease rates vary
between socioeconomic groups, we should measure
the distribution of health across all individuals in a
population.16 This approach is analogous to measuring
inequality in income and would estimate the spread of
health (at an individual or household level) across the
population.
Although superficially attractive, this approach has
major limitations.17 Health is not like income. It is not
possible to assign to each individual in a population an
objective “health” index akin to their income. Aside
from such technical issues, there is also a fundamental
point of principle. The approach would effectively
remove from the picture the reality that health is
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Definitions of inequality and inequity
Inequality
Inequalities in health, formally defined, refer to a broad range of differences
in both health experience and health status between countries, regions, and
socioeconomic groups. Most inequalities are not biologically inevitable but
reflect population differences in circumstances and behaviour that are in
the broadest sense socially determined. However, in industrialised countries
such as the United Kingdom, the term “inequalities in health” has tended to
refer to differences in health status between regions and population
subgroups that are regarded as inequitable.
Inequity
Health inequities, formally defined, are avoidable inequalities that are unfair
and unjust. In reality, however, the term is mainly applied to unfair and
unjust differences in access to health services between regions and
population subgroups within a country. In developing countries, inequities
in access have been the dominant preoccupation of those working on
health inequalities and inequities.
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socially patterned. Although measures of the distribu›
tion of individual health status have a role, they cannot
provide insight into the social and biological
mechanisms that shape the distribution of health
within populations, or what specific interventions are
needed to make them more equitable.
Conceptual and methodological difficulties in the
measurement of inequalities in health are com›
pounded by the problem that only high income coun›
tries have the necessary infrastructure to collect the
relevant routine data. Even in countries where basic
demographic data on population and mortality and
health are collected, they often do not exist in a form
that allows the distribution of health status within
countries to be estimated. However, there are
encouraging signs that some progress is being made.
Data from sample surveys carried out by the World
Bank in a large number of developing countries were
recently used for the first time to make comparable
estimates of socioeconomic differences in self reported
health.18
Aetiological understandings
Our understanding of the aetiological mechanisms that
drive socioeconomic differences in health varies accord›
ing to disease and context. Some of the links between
absolute poverty and ill health are well understood. For
example, poor housing, sanitation, and hygiene can lead
to increased exposure to communicable diseases, and
malnourishment reduces resistance to infection. How›
ever, even among those living in absolute poverty, there
seem to be differences in the extent to which parents are
able to use their scant resources to influence their
children’s morbidity and mortality.19 This underlines the
need to develop people’s capacities and resourcefulness
within broader strategies to reduce the effects of
absolute deprivation on health.
Understanding inequalities in the occurrence of
non›communicable diseases such as cancer and heart
disease has been more challenging. Although contem›
porary socioeconomic differences in mortality from
lung cancer are explained by historical differences in
tobacco smoking, explanations of socioeconomic
gradients for other non›communicable diseases such
as cardiovascular disease have been more problematic.
Various competing theories have been developed. One
important area of debate concerns how far socioeco›
nomic gradients in health are due to deprivation gen›
erating a “general susceptibility” to a wide range of
diseases. The contrasting view is that specific explana›
tions are required for the socioeconomic gradients of
each individual disease.
General susceptibility has also been used to explain
the hypothesised direct association between income
inequality and mortality in high income countries.20
Inequality in income and its correlates (such as level of
social capital and cohesion) are thought to generate a
range of ill health and disease, partly through a
psychosocial stress mechanism. This hypothesis has
been challenged,21 not least because it effectively denies
the observed heterogeneity of socioeconomic gradi›
ents and the existence of distinct (even if overlapping)
aetiologies for specific diseases.
Recently, interest has been increasing in the role of
influences that operate throughout life.22 The imprints
of these influences will not all be equally visible in
adulthood and hence may be overlooked by studies
that have information about individuals only in middle
and old age. The lifecourse approach emphasises the
aetiological specificity of different conditions23 and
throws light not only on inequalities within countries
but also on those between countries.24
The emphasis on factors operating across the life›
course highlights a neglected question that has
potentially major policy implications. Little thought
has been given to considering the timescale over
which changes in the circumstances of different socio›
economic groups could translate into differences in
health status. If there are substantial lag periods
between exposure and onset of disease, as seems to be
the case for many non›communicable diseases, policy
induced changes in conditions today may take
years or even decades to produce reductions in
inequalities in health. This, however, is not a counsel of
despair; it should motivate clearer thinking about the
timescales over which policies can be realistically
expected to yield benefits and thus lead to effective
strategies that are better insulated from the short term
pressures to which politicians and policy makers are
subject.
Conclusions
The issues we have highlighted reflect the complexity
of the scientific, conceptual, and policy issues inherent
in addressing the issues of poverty, inequality, and
health. The way that the problem is perceived, the pri›
ority given to it, and the solutions advanced vary widely
according to ideology, country, and region. To be effec›
tive, action must be rooted in better understanding of
the full scope of current knowledge.
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Lesson of the week
Raised cortisol excretion rate in urine and contamination
by topical steroids
Christopher J G Kelly, Arla Ogilvie, John R Evans, David Shapiro, A Michael Wallace, David L Davies
The clinical features of type 2 diabetes (obesity, hyper›
tension, and glycosuria) often overlap with those of
Cushing’s syndrome, and as impaired glucose toler›
ance occurs in up to 20% of patients with Cushing’s
syndrome, its incidence in people with diabetes is
higher than among people without diabetes.1 Diagno›
sis relies on clinical suspicion and abnormal results of
biochemical tests. Measurement of the excretion rate of
free cortisol in the urine forms the basis of the initial
outpatient investigations and should reflect the overall
cortisol secretion provided it is measured accurately.
We present two cases from diabetic clinics in which
patients had raised urinary free cortisol excretion rates
as a result of urinary contamination by vaginal cream
containing hydrocortisone.
Case reports
Case 1—A 49 year old woman with type 2 diabetes
mellitus, hypertension, and depression was referred for
investigation of possible Cushing’s syndrome. The his›
tory was of deteriorating control of glycaemia and
blood pressure. Outpatient measurement of overnight
urinary cortisol:creatinine ratios showed grossly raised
values (mean 255 ìmol cortisol/mol creatinine; range
15›1191; normal < 25 ìmol/mol creatinine). She was
admitted and underwent a series of complex tests to
define her Cushing’s syndrome, all of which yielded
normal results. Despite this, the urinary free cortisol
excretion rate remained high (4365 nmol/24 hour;
normal rate < 250 nmol/24 hour). This pattern
strongly suggested the presence of a factor interfering
in the measurement of urinary free cortisol, which we
confirmed using gas chromatography. This showed
excipients consistent with the use of topical steroid
cream. Further questioning of the patient revealed that
she had been using an antifungal cream containing
hydrocortisone (Canesten HC, Baypharm, Bayer,
Berks) for vaginal candidiasis. Once this was stopped,
urinary free cortisol excretion rates returned to normal
(120 nmol/24 hour).
Case 2—A 38 year old woman with type 2 diabetes,
gross obesity, and facial plethora also underwent inves›
tigations for Cushing’s syndrome. Overnight urinary
cortisol:creatinine ratios were again moderately raised
over a two month period (range 14 to 137 ìmol/mol
creatinine; normal < 25 ìmol/mol creatinine), but
serum cortisol concentrations were within reference
limits with a normal diurnal variation and a normal
result of an overnight dexamethasone suppression test.
Because of the similarity with case 1, the patient was
interviewed and also admitted using Canesten HC
cream on perineal and vaginal areas to treat candidia›
sis. After she discontinued this treatment, urinary corti›
sol:creatinine ratios returned to normal on all three
occasions tested (5, 11, and 11 ìmol/mol creatinine).
Discussion
In both patients contamination of their urine with
Canesten HC during collection was responsible for the
increased urinary cortisol values. This cream contains
1% hydrocortisone and a normal application is about
0.5 g. Direct contamination with as little as 0.035 mg of
cream (0.007% of that applied) would raise urinary free
cortisol concentration to above the normal range. Uri›
nary free cortisol measurements are often used as an
initial inexpensive screening test for patients with clini›
cal symptoms of Cushing’s syndrome. The pitfalls of
the test are many and include incomplete 24 hour col›
lection, solutes interfering with the competitive
binding assay, and the presence in the urine of admin›
istered steroids.2 3 Steroids are administered by numer›
ous routes, and the above cases show that before
investigations are conducted patients should be asked
if they are using any topical preparation, as drugs given
topically are often not considered a medication by the
patient and consequently not mentioned.
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care. AMW, DS, and JRE were responsible for the biochemical
analysis and advised on biochemical investigations. CJGK and
AO jointly wrote the paper, and AMW, DS, JRE, and DLD
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